Prognostic value of bedside lung ultrasound score in patients with COVID-19

Li Ji
Wuhan Union Hospital

Chunyan Cao
Wuhan Union Hospital

Ying Gao
Wuhan Union Hospital

Wen Zhang
Wuhan Union Hospital

Yuji Xie
Wuhan Union Hospital

Yilian Duan
Wuhan Union Hospital

Shuangshuang Kong
Wuhan Union Hospital

Manjie You
Wuhan Union Hospital

Rong Ma
Wuhan Union Hospital

Lili Jiang
Wuhan Union Hospital

Jie Liu
Wuhan Union Hospital

Zhenxing Sun
Wuhan Union Hospital

Ziming Zhang
Wuhan Union Hospital

Jing Wang
Wuhan Union Hospital

Yali Yang
Wuhan Union Hospital

Qing Lv
Wuhan Union Hospital

Li Zhang
Wuhan Union Hospital

Yuman Li (liym@hust.edu.cn)
Wuhan Union Hospital

Jinxiang Zhang (zhangjinxiang@hust.edu.cn)
Wuhan Union Hospital

Mingxing Xie (xiemx@hust.edu.cn)
Wuhan Union Hospital

Research

Keywords: COVID-19, Lung ultrasound, LUS score, acute respiratory distress syndrome (ARDS), prognosis

Posted Date: November 17th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-55111/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on December 22nd, 2020. See the published version at https://doi.org/10.1186/s13054-020-03416-1.
Abstract

**Background:** Bedside lung ultrasound (LUS) has emerged as a useful and noninvasive tool to detect lung involvement and monitor changes in patients with coronavirus disease 2019 (COVID-19). However, the clinical significance of the LUS score in patients with COVID-19 remains unknown. We aimed to investigate the prognostic value of the LUS score in patients with COVID-19.

**Methods:** The LUS protocol consisted of 12 scanning zones and was performed in 280 consecutive patients with COVID-19. The LUS score based on B-lines, lung consolidation and pleural line abnormalities was evaluated.

**Results:** The median time from admission to LUS examinations was 7 days (interquartile range [IQR] 3-10). Patients in the highest LUS score group were more likely to have a lower lymphocyte percentage (LYM%); higher levels of D-dimer, C-reactive protein, hypersensitive troponin I and creatine kinase muscle-brain; more invasive mechanical ventilation therapy; higher incidence of ARDS; and higher mortality than patients in the lowest LUS score group. After a median follow-up of 14 days [IQR, 10-20 days], 37 patients developed ARDS, and 13 died. Patients with adverse outcomes presented a higher rate of bilateral involvement; more involved zones and B-lines, pleural line abnormalities and consolidation; and a higher LUS score than event-free survivors. The Cox models adding the LUS score as a continuous variable (hazard ratio [HR]: 1.05, 95% confidence intervals [CI]: 1.02–1.08; P < 0.001; Akaike Information Criterion [AIC] =272; C-index = 0.903) or as a categorical variable (HR: 10.76, 95% CI: 2.75–42.05; P = 0.001; AIC =272; C-index = 0.902) were found to predict poor outcomes more accurately than the basic model (AIC =286; C-index = 0.866). An LUS score cut-off >12 predicted adverse outcomes with a specificity and sensitivity of 90.5% and 91.9%, respectively.

**Conclusions:** The LUS score devised by our group performs well at predicting adverse outcomes in patients with COVID-19 and is important for risk stratification in COVID-19 patients.

Background

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global threat, resulting in severe illnesses such as acute respiratory distress syndrome (ARDS), multi-organ dysfunction syndrome, and even mortality. Since there is no specific medicine to cure COVID-19, supportive care is the major treatment during hospitalization. Close follow-up and medicine to relieve symptoms are sufficient for non-critically ill patients, while for severe and critically ill patients, aggressive treatment and admission to intensive care unit (ICU) are needed. However, many non-critically ill patients at admission may deteriorate suddenly during hospitalization. Consequently, early prediction of disease progression may be fundamental in delivering appropriate health care for COVID-19 patients. Several demographic and clinical parameters have been recently shown to have some value for risk stratification in the development of the disease. However, COVID-19 is a kind of respiratory disease, and the lungs are the major organ affected. Therefore, quantitative...
imaging data regarding lung lesions may be essential for in-hospital care to aid in identifying those who may benefit from more intensive monitoring and treatment.

Lung ultrasound (LUS) imaging is a fast, noninvasive, sensitive, and quantitative tool to assess multiple pulmonary pathologies, such as pulmonary oedema, pneumonia and interstitial lung disease. More recently, LUS has also been used to detect lung involvement and monitor changes in patients with COVID-19, especially children and pregnant women. Indeed, ultrasound is the sole imaging modality with accessibility to the bedside of patients for timely identification of pulmonary and other organ complications, reducing the risk of contagiousness and the need to move unstable patients. Recent studies have shown that LUS is an independent predictor of adverse outcomes in patients with pulmonary disease; however, the prognostic significance of LUS in patients with COVID-19 is unclear. Therefore, the purpose of this study was to investigate whether the LUS score at admission was independently predictive of poor outcomes in patients with COVID-19.

**Methods**

**Study Design and Population**

This was a prospective, single-centre, observational study that included 280 consecutive patients from the designated hospital to treat COVID-19 patients, the west and tumour branch of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from January 21, 2020, to March 10, 2020. Inclusion criteria consisted of COVID-19 diagnosis according to the interim guidance of the World Health Organization, with age >18 years. The exclusion criteria were as follows: heart failure, interstitial pneumonia, tuberculosis, bronchiectasis, chronic obstructive pulmonary disease (COPD), other pulmonary disease hampering image acquisition (significant pleural effusion, previous pneumectomy, breast prosthesis), or suboptimal ultrasound window.

The study complied with the edicts of the 1975 Declaration of Helsinki and was approved by the institutional ethics board of Union Hospital Tongji Medical College, Huazhong University of Science and Technology. Written informed consent was waived for all participants with emerging infectious diseases.

**Clinical Data and Outcomes**

Patients’ demographic characteristics, symptoms, laboratory tests, comorbidities, complications, treatment, and outcomes were extracted from electronic medical records by a single investigator. Laboratory tests were recorded only if they were obtained within 7 days of admission. These data were independently reviewed and entered into the computer database by two analysts (L.L.J. and R.M.).

The outcomes included: (1) in-hospital mortality; (2) ARDS. The primary endpoint of the study was in-hospital mortality, and ARDS was the secondary endpoint. All prespecified outcomes were confirmed through patient electronic medical records and evaluated by two experienced investigators (J.L. and
M.J.Y.) who were blinded to the ultrasound data. ARDS was defined according to the Berlin Definition.\textsuperscript{19} The final follow-up date was March 25, 2020.

**Lung Ultrasound Imaging Protocol and Analysis**

Lung ultrasound examinations were performed by trained sonographers (Y.L.D., W.Z., S.S.K., Z.M.Z. and Z.X.S.) using portable ultrasound equipment (Mindray M7, M8, M9 and GE Logiq E9) with a 1-6 MHz convex transducer. The unilateral lung was divided into anterior, lateral and posterior fields using anterior and posterior axillary lines, and each field was divided into superior and inferior areas using two axial lines (one above the diaphragm and the other 1 cm above the nipples). A total of 12 regions were assessed using a two-dimensional view with the probe placed perpendicular to the chest wall and evaluated for the following signs: pleural line (a horizontal hyperechoic line between the ribs), A-lines (horizontal reverberation artefacts repeated at a constant distance equal to the distance between pleural line and probe surface), B-lines (vertical hyperechoic reverberation artefacts deriving from the pleural line) and consolidation (presence of a tissue-like pattern).\textsuperscript{20-21}

Offline image analysis was performed by two investigators (L.J. and C.Y.C.) with experience in LUS who were blinded to the clinical data and other radiologic features. Images were evaluated independently. After separate evaluations, final decisions were reached by consensus. In each region, LUS signs including B-lines/consolidation and pleural line abnormalities were assessed, and the worst ultrasound pattern was recorded. B-lines/consolidation were quantitatively scored according to a previous study\textsuperscript{21}:

1. score 0: well-spaced B-lines <3;
2. score 1: well-spaced B-lines $\geq$ 3;
3. score 2: multiple coalescent B-lines;
4. score 3: lung consolidation. The pleural line was quantitatively scored as follows:
   1. score 0: normal;
   2. score 1: irregular pleural line;
   3. score 2: blurred pleural line. A composite score of each region was calculated by summing the individual scores for B-lines/consolidation (score 0-3) and pleural abnormalities (score 0-2). The sum of the scores in all twelve zones yielded a final score of the COVID-19 patient (ranging from 0 to 60), defined as the LUS score. Typical lung ultrasound and corresponding lung computerized tomography (CT) images of patients with various LUS score are shown in Figure 1.

**Statistical Analysis**

Continuous variables are expressed as the mean ± SD or median (interquartile range [IQR]), as appropriate. Categorical variables are presented as frequencies (percentages). Continuous variables were compared using analysis of variance (ANOVA) for normally distributed data or the Mann-Whitney U test for non-normally distributed data. Categorical variables were compared using the chi-square test or Fisher’s exact test. Estimations of the predictor of adverse events were performed using univariate and multivariate Cox regression models. All potential predictors of adverse outcomes were entered into univariate analyses. Variables with $P < 0.001$ in univariate analysis were entered into multivariate Cox regression models. For multivariable analysis, a separate model including clinical variables and LUS score was used to determine the independent predictors of poor outcome. Model performance was assessed using the Akaike information criterion (AIC) and the C-index. Receiver operator curve (ROC)
analysis was performed to examine the sensitivity and specificity of prognosis parameters for adverse events and to determine the best cut-off value (maximum Youden index) for predicting future events. Kaplan-Meier curves were used to examine cumulative event rates, and differences between groups were tested using the log rank test. A two-sided value of $P < 0.05$ was considered significant. Statistical analyses were performed using SPSS version 22.0 (SPSS Inc, Chicago, Illinois), R-language 4.0.1 and MedCalc Version 19.0.7 (MedCalc Software, Ostend, Belgium).

Results

Clinical Characteristics

A total of 280 patients with COVID-19 who met the inclusion criteria were identified (age, 55 years [IQR, 40-65 years]; gender, 141 male), including 153 (54.6%) with low LUS score, 70 (25%) with moderate LUS score and 57 (20.4%) with high LUS score. Table 1 summarizes the baseline clinical characteristics of the patients stratified by the level (low, moderate, high) of the LUS score. Patients in the high LUS score group were older and had a significantly higher incidence of comorbidities (including hypertension, diabetes, chronic cardiovascular disease and malignancy), lower LYM% and SO$_2$%, higher levels of CRP, D-dimer, hs-TnI and CK-MB, and lower oxygenation index than patients in the low and moderate LUS score groups. There were no significant differences in gender, BMI, respiratory rate at admission or the prevalence of chronic liver disease in patients with COVID-19 among the low, moderate and high LUS score groups. More patients with higher LUS score were treated with medicines (antiviral, antibiotic and glucocorticoid) and high-flow oxygen than those with lower LUS score. Only patients with high LUS score received invasive mechanical ventilation (n=17) therapy and admission to the ICU (n=17).

During hospitalization, 73 patients developed complications (respiratory failure, 49; ARDS, 37; sepsis, 14; acute heart injury, 40; acute kidney injury, 26), and patients with higher LUS score were more likely to have a higher proportion of these complications. Thirteen patients with high LUS score died, and 267 patients were discharged. Patients with low and moderate LUS score did not die during hospitalization.

After a median follow-up of 14 days [IQR, 10-20 days], 37 patients developed ARDS, and 13 died. All non-surviving patients had ARDS. The clinical data of patients with and without adverse events are listed in Table 2. Patients with adverse events were older and had a significantly higher incidence of comorbidities (including hypertension, diabetes, chronic cardiovascular disease and malignancy), lower LYM% and SO2%, higher levels of CRP, D-dimer, hs-TnI and CK-MB, and lower oxygenation index than patients without adverse events. More patients with adverse events were treated with medicines (antiviral, antibiotic and glucocorticoid) and high-flow oxygen than those without adverse events. Only patients with adverse events received invasive mechanical ventilation (n=17) therapy and admission to the ICU (n=17).

LUS Characteristics

The median time from admission to LUS examinations was 7 days (interquartile range [IQR] 3-10). In this study, the most common LUS abnormalities in COVID-19 patients were various forms of B-lines (including
well-spaced and multiple coalescent B-lines, 75%), followed by pleural line abnormalities (including irregular and blurred pleural line, 46.5%) and lung consolidation (16.4%). Pleural effusion was uncommon. The LUS characteristics of patients with low, moderate and high LUS score are shown in Table 3. Patients with high LUS score were more likely to have bilateral involvement, lung consolidation, pleural line abnormalities, and more B-lines and involved zones. The LUS characteristics of patients with and without adverse events are listed in Table 4. The adverse event group had a higher LUS score (32 vs. 1, p<0.001) than the nonevent group. Patients with adverse outcomes were more likely to have a higher rate of irregular pleural line (97.3% vs. 25.9%, p<0.001), blurred pleural line (67.6% vs. 2.5%, p<0.001), multiple coalescent B-lines (70.3% vs. 3.3%, p<0.001), and lung consolidation (64.9% vs. 9.1%, p<0.001).

**Determination of discrimination abilities of independent predictors of adverse outcomes**

ROC curve analysis was used to assess the predictive values of these three independent predictors (age, LYM%, LUS score) for adverse events during hospitalization. Our results showed that the areas under the curves of LUS score, age and LYM% were 0.95, 0.85, and 0.83, respectively (p<0.001) (Figure 2). The area under the curve of the LUS score was greater than that of age (0.95 vs 0.85, p<0.001) and LYM% (0.95 vs 0.83, p<0.001). A cut-off value of 12 for the LUS score at admission had a sensitivity of 91.9% and a specificity of 90.5% for the prediction of adverse outcomes in patients with COVID-19.

Kaplan-Meier analysis showed that patients with a comorbidity, LUS score > 12, LYM% ≤ 18.55% or age > 59 years were associated with adverse events during hospitalization (Figure 3).

**Predictors of adverse outcomes in patients with COVID-19**

Univariate Cox regression analysis revealed that age (HR: 1.081, 95% CI: 1.057~1.106; P < 0.001), LYM% (HR: 0.872, 95% CI: 0.836~0.909; P<0.001), comorbidity (HR: 4.928, 95% CI: 2.417~10.050; P<0.001), and LUS score (HR: 1.083, 95% CI: 1.065~1.100; P<0.001) at admission were significantly associated with adverse events during hospitalization (Table 4). In multivariate Cox analysis models, older age and lower LYM% remained predictive of adverse outcomes; however, presence of a comorbidity was no longer associated with poor outcomes. The LUS score remained a continuous variable in model 2 and was transformed into a categorical variable according to ROC cut-off points in model 3. The models with clinical parameters and LUS score as a continuous variable (HR: 1.049, 95% CI: 1.023~1.078; P<0.001; AIC=272; C-index=0.903) or as a categorical variable (HR: 10.76, 95% CI: 2.75~42.05; P=0.001; AIC=272; C-index=0.902) were better in predicting adverse events compared with the basic risk model (age, LYM% and comorbidity) (AIC = 286; C-index = 0.866). (Table 5).

**Discussion**

In this study, patients with the highest LUS score were more likely to have higher elevated levels of cardiac injury, coagulopathy and inflammatory biomarkers, more mechanical ventilation therapy, higher incidence of respiratory failure, ARDS, and sepsis, and higher mortality. Patients with adverse events presented a higher rate of bilateral involvement, more involved zones, B-lines, pleural line abnormalities
and consolidation, and a higher LUS score than event-free survivors. More importantly, the LUS score was able to predict a higher risk of adverse events in patients with COVID-19 independently. Therefore, the LUS score may be essential for risk stratification in COVID-19 patients.

Although chest CT has played a crucial role in characterizing pulmonary lesions during the COVID-19 pandemic, the increasing risk of infection and the need to move unstable patients make chest CT a limited choice. The histopathology of pulmonary lesions in COVID-19 patients begins in subpleural regions and is characterized by alveolar damage and oedema, interstitial thickening and consolidation. Furthermore, lesions of this disease are mainly located peripherally and subpleurally. Therefore, ultrasound can identify pulmonary lesions in a timely and sensitive manner. Most patients in our cohort showed bilateral and posterior field involvement, which is consistent with chest CT features. In our study, the predominant LUS abnormality of COVID-19 was B-lines (75%). Patients in our cohort also presented with irregular (35.4%) or blurred (11.1%) pleural line and lung consolidation (16.4%) on LUS. These imaging features characterized in our study are similar to prior studies targeting patients with COVID-19.

A previous study showed that the median time from illness onset to ARDS was 12 days (9.5-17.0), and the median time from illness onset to death was 18.5 days (15.0-22.0). A recent observation regarding the lung changes on chest CT demonstrated that the involvement of lung area and dense consolidation increased to the peak at 9-13 days after symptom onset. In our study, due to the personnel and resource constraints in the early stage of pandemic, we performed LUS examination with some delay. The median time from admission to LUS examinations was 7 (3-10) days and the median time from illness onset to LUS examinations was 10 days (IQR 5-15). Therefore, we acknowledged that some patients maybe at the peak of the disease when performed LUS examinations. In addition, we described serial bedside LUS and corresponding CT findings in a severe (Supplementary material Figure 1) and a mild (Supplementary material Figure 2) COVID-19 patient to illustrate that performing LUS with some delay allowed the pulmonary lesions and LUS findings to be better developed. In recent studies, CT scans were performed both in the early-phase (within one week) and late-phase (one week later after symptom onset) COVID-19 patients. Their data showed that radiological findings can accurately predict poor outcome irrespective of the disease course. Accordingly, we reckon that the LUS score devised by our group may also have the predictive value in the late-phase patients.

There are several reports regarding lung score. In intensive care units, the most frequently used score distinguishes four steps of progressive loss of aeration, A-lines or two or fewer B-lines (normal aeration, score 0), three or more well-spaced B-lines (moderate loss of aeration, score 1), coalescent B-lines (severe loss of aeration, score 2), and a tissue-like pattern (complete loss of aeration, score 3). In heart failure patients, the number and spatial extent of B-lines on the antero-lateral chest is usually summed to generate a B-line score to estimate extravascular lung water (EVLW) semi-quantitatively (B-lines ≤ 5, score 0; 6-15, score 1; 16-30, score 2; >30, score 3). These lung score, which were based on B-lines, can provide useful information regarding the presence and degree of pulmonary lesions. B-lines are
nonspecific artefacts associated with increased extravascular lung water or partial loss of lung aeration,\textsuperscript{20} and they can be detected in a variety of pulmonary diseases, including interstitial lung disease, heart failure, acute respiratory distress syndrome, etc. However, LUS manifestations in COVID-19 patients shared not only the features of an increase in B-lines but also consolidations, irregular or blurred pleural line. The comprehensive assessment of these abnormalities can accurately reflect lung involvement and then serve as a predictor of poor outcomes in patients with COVID-19. Therefore, we proposed the LUS score as an LUS quantitative indicator, which takes into account multiple LUS signs, such as the number of B-lines, consolidation or not, and pleural line changes.

There are limited data regarding the prognostic value of the LUS score in pulmonary disease. In a recent study of 40 elderly patients, Bouhemad et al found that LUS alone may identify elderly patients at high risk of weaning or extubation failure.\textsuperscript{33} Another observation was reported by Platz et al., who demonstrated that pulmonary congestion assessed by ultrasound is associated with other features of clinical congestion and identified those who have a worse prognosis.\textsuperscript{34} Similarly, residual pulmonary congestion assessed by a B-line count \( \geq 30 \) is a strong predictor of all-cause death or heart failure hospitalization.\textsuperscript{35} These studies employed LUS, which was based on B-lines, for the prediction of pulmonary disease. In our study, we identified that patients with poor outcomes presented a higher rate of bilateral involvement, more involved zones and B-lines, pleural line abnormalities and consolidation, and a higher LUS score. These results revealed that the number of B-lines and the extent of lung consolidation and pleural line abnormality increased with illness severity, suggesting that the LUS score may aid in the classification of disease severity and triage of COVID-19 patients.

COVID-19 can lead to varying degrees of illness, and some patients with mild symptoms at admission may progress rapidly during hospitalization.\textsuperscript{3} It is significant to recognize patients with COVID-19 at higher risk for adverse outcomes who might benefit from watchful monitoring. Prior research suggests that patients with COVID-19 who had an older age, lymphopenia, elevated CRP, or comorbidity are at higher risk for adverse outcome and death.\textsuperscript{4-7} However, quantitative imaging data characterizing the pulmonary lesions would help us to identify patients who are at higher risk of poor outcomes. To the best of our knowledge, this is the first study to assess the prognostic implication of the LUS score in patients with COVID-19. Indeed, patients with a higher LUS score were more likely to experience more adverse clinical events, including mortality or ARDS. Patients with adverse outcomes presented more B-lines, a wider range of pleural line abnormalities and consolidation and a higher LUS score. The LUS score was able to predict a higher risk of adverse outcomes in COVID-19 patients, independent of and incrementally to other clinical parameters. A higher LUS score was not specific for COVID-19-associated lung injury but instead could identify the patients at higher risk for poor outcome.

Several limitations of our study should be highlighted. This was a single-centre study with a relatively limited sample size, which could limit the generalizability of our results. Therefore, further multi-centre studies with a larger sample size are needed to assess the prognostic value of the LUS score in patients with COVID-19. Moreover, LUS can only evaluate peripheral lesions due to echo attenuation, and the
actual severity of lung involvement in this cohort may be underestimated. Furthermore, due to the personnel and resource constraints in the early stage of pandemic, we performed LUS examination with some delay, which may limit the prognostic value of LUS score in our study. Additionally, we excluded some patients due to a suboptimal ultrasound window, which might have introduced a bias. Finally, a comparison between the LUS score and chest CT was not performed because we had extremely limited CT image data.

Conclusions

The LUS score devised by our group performs well at predicting adverse outcomes in patients with COVID-19 and is important for risk stratification in COVID-19 patients.

Abbreviations

ARDS: acute respiratory distress syndrome; AIC: akaike information criterion; ANOVA: analysis of variance; AUC: area under curve; BMI: body mass index; COVID-19: coronavirus disease 2019; C-index: concordance index; CK-MB: creatine kinase muscle-brain; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; CT: computerized tomography; hs-TnI: hypersensitive troponin I; HR: hazard ratio; IQR: interquartile range; ICU: intensive care unit; LYM%: lymphocyte percentage; LUS: lung ultrasound; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SD: standard deviation.

Declarations

Acknowledgements

We would like to thank all the medical workers involved in the rescue and the staff for collection of the data in Wuhan.

Author contributions

MXX and JXZ designed the study and were guarantor of the paper. LJ and CYC prepared the draft and finalized the manuscript. YML and YG helped with data analysis and interpretation of the results. YML also reviewed the manuscript. LLJ, RM, JL, and MJY were involved in clinical data collection and arrangement. YLD, WZ, SSK, ZMZ, and ZXS participated in ultrasound imaging acquisition in isolation wards. LJ and CYC performed offline LUS imaging analysis. All authors contributed to provide comments on the manuscript.

Ethics approval and consent to participate

The study was approved by the institutional ethics board of Union hospital Tongji Medical College, Huazhong University of Science and Technology.

Consent for publication
Consent for publication was obtained from all participants. Written informed consent was waived for all participants with emerging infectious diseases.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81727805, 81922033, 81401432).

**References**

1. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020;55(6):2000562. doi:10.1183/13993003.00562-2020

2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.

3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

4. Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.0994

5. Huang G, Kovalic AJ, Graber CJ. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity. Emerg Infect Dis. 2020. doi: 10.3201/eid2608.201160

6. Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa641

7. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.

8. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30434-5

9. Ferré A, Guillot M, Lichtenstein D, et al. Lung ultrasound allows the diagnosis of weaning-induced pulmonary oedema. Intensive Care Med. 2019;45(5):601-608.
10. Wang G, Ji X, Xu Y, Xiang X. Lung ultrasound: a promising tool to monitor ventilator-associated pneumonia in critically ill patients. Crit Care. 2016;20(1):320.

11. Barskova T, Gargani L, Guiducci S, et al. Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann Rheum Dis. 2013;72(3):390-395.

12. Denina M, Scolfaro C, Silvestro E, et al. Lung Ultrasound in Children with COVID-19. Pediatrics. 2020. doi:10.1542/peds.2020-1157

13. Youssef A, Serra C, Pilu G. Lung Ultrasound in the COVID-19 Pandemic: A Practical Guide for Obstetricians and Gynecologists. Am J Obstet Gynecol. 2020;223(1):128–131.

14. Wang B, Zhang L, Zhang D, et al. Bedside Ultrasound in Assessment of 510 Severe and Critical Patients with COVID-19 Pneumonia in Wuhan, China. Advanced Ultrasound in Diagnosis and Therapy. 2020; 4(2): 60-66.

15. Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. Eur J Heart Fail. 2017;19(9):1154-1163.

16. Gargani L, Bruni C, Romei C, et al. Prognostic value of lung ultrasound B-lines in systemic sclerosis. Chest. 2020. doi: 10.1016/j.chest.2020.03.075

17. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Published March 13, 2020. Accessed January 28, 2020. 20. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)infection-is-suspecte.

18. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310:2191-2194.

19. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.

20. Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38(4):577-591.

21. Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung Ultrasound for Critically Ill Patients. Am J Respir Crit Care Med. 2019;199(6):701-714.

22. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-434.

23. Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295(1):202-207.

24. Volpicelli G, Lamorte A, Villén T. What's new in lung ultrasound during the COVID-19 pandemic. Intensive Care Med. 2020 4:1–4.

25. Peng QY, Wang XT, Zhang LN. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic. Intensive Care Med. 2020;46(5):849-850.
26. Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. Anaesthesia. 2020. doi: 10.1111/anae.15082

27. Ji L, Li Y, Cao C, Lv Q, Xie M. Serial bedside lung ultrasonography in a critically ill COVID-19 patient. QJM. 2020;113(7):491-493. doi:10.1093/qjmed/hcaa141

28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

29. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020 Jun; 295(3):715-721. doi: 10.1148/radiol.2020200370.

30. Wu Q, Wang S, Li L, et al. Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19. Theranostics. 2020 Jun 5;10(16):7231-7244. doi: 10.7150/thno.46428.

31. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. Theranostics. 2020 Mar 15;10(10):4606-4613. doi: 10.7150/thno.45016.

32. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J. 2016;37(27):2097-2104. doi:10.1093/eurheartj/ehw164

33. Bouhemad B, Mojoli F, Nowobilski N, et al. Use of combined cardiac and lung ultrasound to predict weaning failure in elderly, high-risk cardiac patients: a pilot study. Intensive Care Med. 2020;46(3):475-484.

34. Platz E, Lewis EF, Uno H, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37(15):1244-1251.

35. Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17(11):1172-1181.

1. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020;55(6):2000562. doi:10.1183/13993003.00562-2020

2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.

3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

4. Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.0994

5. Huang G, Kovalic AJ, Graber CJ. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity. Emerg Infect Dis. 2020. doi: 10.3201/eid2608.201160
6. Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa641

7. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.

8. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30434-5

9. Ferré A, Guillot M, Lichtenstein D, et al. Lung ultrasound allows the diagnosis of weaning-induced pulmonary oedema. Intensive Care Med. 2019;45(5):601-608.

10. Wang G, Ji X, Xu Y, Xiang X. Lung ultrasound: a promising tool to monitor ventilator-associated pneumonia in critically ill patients. Crit Care. 2016;20(1):320.

11. Barskova T, Gargani L, Guiducci S, et al. Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann Rheum Dis. 2013;72(3):390-395.

12. Denina M, Scolfaro C, Silvestro E, et al. Lung Ultrasound in Children with COVID-19. Pediatrics. 2020. doi:10.1542/peds.2020-1157

13. Youssef A, Serra C, Pilu G. Lung Ultrasound in the COVID-19 Pandemic: A Practical Guide for Obstetricians and Gynecologists. Am J Obstet Gynecol. 2020;223(1):128–131.

14. Wang B, Zhang L, Zhang D, et al. Bedside Ultrasound in Assessment of 510 Severe and Critical Patients with COVID-19 Pneumonia in Wuhan, China. Advanced Ultrasound in Diagnosis and Therapy. 2020; 4(2): 60-66.

15. Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. Eur J Heart Fail. 2017;19(9):1154-1163.

16. Gargani L, Bruni C, Romei C, et al. Prognostic value of lung ultrasound B-lines in systemic sclerosis. Chest. 2020. doi: 10.1016/j.chest.2020.03.075

17. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Published March 13, 2020. Accessed January 28, 2020. 20. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)infection-is-suspecte.

18. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310:2191-2194.

19. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.

20. Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38(4):577-591.

21. Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung Ultrasound for Critically Ill Patients. Am J Respir Crit Care Med. 2019;199(6):701-714.
22. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-434.

23. Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295(1):202-207.

24. Volpicelli G, Lamorte A, Villén T. What's new in lung ultrasound during the COVID-19 pandemic. Intensive Care Med. 2020 4:1–4.

25. Peng QY, Wang XT, Zhang LN. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic. Intensive Care Med. 2020;46(5):849-850.

26. Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. Anaesthesia. 2020. doi: 10.1111/anae.15082

27. Ji L, Li Y, Cao C, Lv Q, Xie M. Serial bedside lung ultrasonography in a critically ill COVID-19 patient. QJM. 2020;113(7):491-493. doi:10.1093/qjmed/hcaa141

28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

29. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020 Jun; 295(3):715-721. doi: 10.1148/radiol.2020200370.

30. Wu Q, Wang S, Li L, et al. Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19. Theranostics. 2020 Jun 5;10(16):7231-7244. doi: 10.7150/thno.46428.

31. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. Theranostics. 2020 Mar 15;10(10):4606-4613. doi: 10.7150/thno.45016.

32. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J. 2016;37(27):2097-2104. doi:10.1093/eurheartj/ehw164

33. Bouhemad B, Mojoli F, Nowobilski N, et al. Use of combined cardiac and lung ultrasound to predict weaning failure in elderly, high-risk cardiac patients: a pilot study. Intensive Care Med. 2020;46(3):475-484.

34. Platz E, Lewis EF, Uno H, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37(15):1244-1251.

35. Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17(11):1172-1181.

Tables
Table 1. Baseline characteristics of patients with COVID-19 according to LUS score

| Variables                        | Total population (n=280) | LUS score | p value |
|----------------------------------|--------------------------|-----------|---------|
|                                 |                          | Low 0-1 (n=153) | Moderate 2-12 (n=70) | High >12 (n=57) | |
| **Demographic data**             |                          |           |         |          | |
| Age, year                        | 55[40~65]                | 46[34~57] | 59[48~68] | 69[60~76] | <0.001 |
| Male, n (%)                      | 141(50.4)                | 73(47.7)  | 37(52.9)  | 31(54.4)  | 0.632  |
| BMI, Kg/m²                       | 23.11±3.31               | 23.24±3.27 | 23.29±3.08 | 23.16±3.27 | 0.957  |
| Temperature, °C                  | 38.4[37.8~38.9]          | 38.0[37.8~38.8] | 38.4[37.8~38.7] | 38.6[38.0~39.0] | 0.042  |
| Respiratory rate, min⁻¹          | 20[19~20]                | 20[18~20]  | 20[18.5~20] | 20[19~21]  | 0.207  |
| SaO₂ (%)                         | 98[97~99]                | 99[98~99]  | 99[98~99]  | 98[95~99]  | 0.014  |
| **Comorbidities, n(%)**          |                          |           |         |          |         |
| Hypertension, n (%)              | 58(20.7)                 | 16(10.5)  | 15(21.4)  | 27(47.4)  | <0.001 |
| Diabetes, n (%)                  | 27(9.6)                  | 4(2.6)    | 6(8.6)    | 17(29.8)  | <0.001 |
| Chronic cardiovascular disease, n (%) | 24(8.6)               | 6(3.9)    | 0(0.0)    | 18(31.6)  | <0.001 |
| Chronic liver diseases, n (%)    | 11(3.9)                  | 4(2.6)    | 2(2.9)    | 5(8.8)    | 0.161  |
| Malignancy, n (%)                | 13(4.6)                  | 2(1.3)    | 2(2.9)    | 9(15.8)   | <0.001 |
| **Laboratory results**           |                          |           |         |          |         |
| Lymphocytes %                    | 24.29±10.88              | 29.18±8.43 | 27.55±8.79 | 14.60±9.32 | <0.001 |
| CRP, mg/L                        | 6.30[2.00~40.13]         | 2.49[0.81~8.49] | 3.40[1.47~10.69] | 27.43[4.18~66.41] | <0.001 |
| D-dimer, ug/L                    | 0.99[0.37~3.70]          | 0.27[0.20~0.94] | 0.34[0.25~1.20] | 1.65[0.85~6.52] | <0.001 |
| hs-TnI, ng/L                     | 2.6[1.4~2.6]             | 2.2[1.4~2.8] | 1.7[0.9~5.3] | 18.3[2.5~113.2] | 0.001 |
| CK-MB, U/L                       | 0.5[0.3~6.0]             | 0.4[0.3~0.6] | 0.4[0.3~0.8] | 7.0[0.4~13.5] | 0.001 |
| **PaO₂:FiO₂, mmHg**              |                          |           |         |          |         |
| >300                             | 246(87.9)                | 153(100.0) | 68(97.1)  | 25(43.9)  | <0.001 |
| 200-300                          | 22(7.9)                  | 0(0.0)    | 2(2.9)    | 20(35.1)  | <0.001 |
| ≤200                             | 12(4.3)                  | 0(0.0)    | 0(0.0)    | 12(21.1)  | <0.001 |
| **Treatments**                   |                          |           |         |          |         |
| Antiviral therapy, n (%)         | 82(29.3)                 | 19(12.4)  | 28(40.0)  | 35(61.4)  | <0.001 |
| **Antibiotic therapy, n (%)** | 78(27.9) | 18(11.8) | 26(37.1) | 34(59.6) | <0.001 |
|-------------------------------|-----------|----------|----------|----------|--------|
| **Glucocorticoid therapy, n (%)** | 22(7.9) | 3(2.0) | 3(4.3) | 16(28.1) | <0.001 |
| **High-flow oxygen, n (%)** | 47(16.8) | 2(1.3) | 3(4.3) | 42(73.7) | <0.001 |
| **Invasive mechanical ventilation, n (%)** | 17(6.1) | 0(0.0) | 0(0.0) | 17(29.8) | <0.001 |
| **ICU admission, n (%)** | 17(6.1) | 0(0.0) | 0(0.0) | 17(29.8) | <0.001 |

**Complications**

| **Respiratory failure, n (%)** | 49(17.5) | 2(1.3) | 3(4.3) | 44(77.2) | <0.001 |
| **ARDS, n (%)** | 37(13.2) | 1(0.7) | 2(2.9) | 34(59.6) | <0.001 |
| **Sepsis, n (%)** | 14(5.0) | 0(0.0) | 0(0.0) | 14(24.6) | <0.001 |
| **Acute heart injury, n (%)** | 40(14.3) | 9(5.9) | 11(15.7) | 20(35.1) | <0.001 |
| **Acute kidney injury, n (%)** | 26(9.3) | 0(0.0) | 6(8.6) | 20(35.1) | <0.001 |

**Prognosis**

| **Discharge, n (%)** | 267(95.4) | 153(100.0) | 70(100.0) | 44(77.2) | <0.001 |
| **Death, n (%)** | 13(4.6) | 0(0.0) | 0(0.0) | 13(22.8) | <0.001 |

Data are n (%), Median [IQR] or mean ± SD. p values comparing patients with COVID-19 in different groups are from χ² test, Fisher's exact test, ANOVA or Mann-Whitney U test. p<0.05 was considered statistically significant. IQR, Inter Quartile Range; BMI, Body Mass Index; CRP, C-reactive protein; hs-TnI, Hypersensitive troponin I; CK-MB, creatine kinase muscle-brain; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019.
Table 2. Baseline characteristics of COVID-19 Patients on admission according to the presence of adverse events

| Variables                              | All patients (n=280) | Non-event (n=243) | Event (n=37) | p value |
|----------------------------------------|----------------------|-------------------|--------------|---------|
| **Demographic data**                   |                      |                   |              |         |
| Age, year                              | 55[40~65]            | 52[38~61]         | 71[63~79]    | <0.001  |
| Male, n (%)                            | 141(50.4)            | 121(49.8)         | 20(54.1)     | 0.725   |
| BMI, Kg/m²                              | 23.11±3.31           | 23.21±3.27        | 21.31±2.96   | 0.129   |
| Temperature, °C                        | 38.4[37.8~38.9]      | 38.1[37.8~38.8]   | 38.6[38.0~39.0] | 0.113   |
| Respiratory rate, min⁻¹                | 20[19~20]            | 20[18~20]         | 20[20~23]    | 0.001   |
| SaO2(%)                                | 98[97~99]            | 99[98~99]         | 97[95~99]    | <0.001  |
| **Comorbidities, n (%)**               |                      |                   |              |         |
| Hypertension, n (%)                    | 58(20.7)             | 42(17.3)          | 16(43.2)     | 0.001   |
| Diabetes, n (%)                        | 27(9.6)              | 14(5.8)           | 13(35.1)     | <0.001  |
| Chronic cardiovascular disease, n (%)  | 24(8.6)              | 11(4.5)           | 13(35.1)     | <0.001  |
| Chronic liver diseases, n (%)          | 11(3.9)              | 8(3.3)            | 3(8.1)       | 0.166   |
| Malignancy, n (%)                      | 13(4.6)              | 6(2.5)            | 7(18.9)      | <0.001  |
| **Laboratory results**                 |                      |                   |              |         |
| Lymphocytes %                          | 24.29±10.88          | 26.92±9.38        | 13.91±10.24  | <0.001  |
| CRP, mg/L                              | 6.30[2.00~40.13]     | 5.44[1.48~27.40]  | 28.2[4.2~85.3] | 0.002   |
| D-dimer, ug/L                          | 0.99[0.37~3.70]      | 0.43[0.26~1.21]   | 2.60[1.06~7.73] | <0.001  |
| hs-TnI, ng/L                           | 2.6[1.4~2.6]         | 1.8[0.9~4.7]      | 22.0[8.6~197.2] | <0.001  |
| CK-MB, U/L                             | 0.5[0.3~6.0]         | 0.4[0.3~0.6]      | 9.0[3.8~30.5] | <0.001  |
| **PaO₂:FiO₂, mmHg**                    |                      |                   |              |         |
| >300                                   | 246(87.9)            | 242(99.6)         | 4(10.8)      | <0.001  |
| 200-300                                | 22(7.9)              | 1(0.4)            | 21(56.8)     | <0.001  |
| <200                                   | 12(4.3)              | 0(0.0)            | 12(32.4)     | <0.001  |
| **Treatments**                         |                      |                   |              |         |
| Antiviral therapy, n (%)               | 82(29.3)             | 58(23.9)          | 24(64.9)     | <0.001  |
| Antibiotic therapy, n (%)              | 78(27.9)             | 54(22.2)          | 24(64.9)     | <0.001  |
| Glucocorticoid therapy, n (%)          | 22(7.9)              | 10(4.1)           | 12(32.4)     | <0.001  |
| High-flow oxygen, n (%)                | 47(16.8)             | 11(4.5)           | 36(97.3)     | <0.001  |
| Invasive mechanical ventilation, n (%) | 17(6.1)              | 0(0.0)            | 17(45.9)     | <0.001  |
| ICU admission, n (%) | 17(6.1) | 0(0.0) | 17(45.9) | <0.001 |

Data are n (%) or median [IQR]. p values comparing patients with COVID-19 in different groups and normal control participants are from χ² test, or Mann-Whitney U test. p<0.05 was considered statistically significant; LUS, lung ultrasonography; COVID-19, coronavirus disease 2019.
Table 3. LUS Characteristics of Patients with COVID-19 according to LUS score

| Variables | Total population (n=280) | Low 0-1 (n=153) | Moderate 2-12 (n=70) | High >12 (n=57) | p value |
|-----------|--------------------------|-----------------|----------------------|------------------|---------|
| **LUS features** | | | | | |
| Pleural line, n (%) | | | | | |
| normal pleural line | 181(64.6) | 152(99.3) | 29(41.4) | 0(0.0) | <0.001 |
| irregular pleural line | 99(35.4) | 1(0.7) | 41(58.6) | 57(100.0) | <0.001 |
| blurred pleural line | 31(11.1) | 0(0.0) | 0(0.0) | 31(54.4) | <0.001 |
| B-lines, n (%) | | | | | |
| well-spaced B-lines<3 | 250(89.3) | 153(100.0) | 70(100.0) | 27(47.4) | <0.001 |
| well-spaced B-lines≥3 | 176(62.9) | 49(32.0) | 70(100.0) | 57(100.0) | <0.001 |
| multiple coalescent B-lines | 34(12.1) | 0(0.0) | 1(1.4) | 33(57.9) | <0.001 |
| Consolidation, n (%) | | | | | |
| Pleural effusion, n (%) | 5(1.8) | 0(0.0) | 0(0.0) | 5(8.8) | <0.001 |
| Distribution of abnormal LUS features | | | | | |
| Irregular pleural line | | | | | |
| anterior fields | 55(19.6) | 1(0.7) | 8(11.4) | 46(80.7) | <0.001 |
| lateral fields | 50(17.9) | 0(0.0) | 5(7.1) | 45(78.9) | <0.001 |
| posterior fields | 76(27.1) | 0(0.0) | 31(44.3) | 45(78.9) | <0.001 |
| No. of involved zones | 0[0~2] | 0[0~0] | 1[0~2] | 6[4~10] | <0.001 |
| Blurred pleural line | | | | | |
| anterior fields | 4(1.4) | 0(0.0) | 0(0.0) | 4(7.0) | 0.002 |
| lateral fields | 16(5.7) | 0(0.0) | 0(0.0) | 16(28.1) | <0.001 |
| posterior fields | 28(10.0) | 0(0.0) | 0(0.0) | 28(49.1) | <0.001 |
| No. of involved zones | 0[0~0] | 0[0~0] | 0[0~0] | 1[0~3] | <0.001 |
| Well-spaced B-lines≥3 | | | | | |
| anterior fields | 100(35.7) | 14(9.2) | 30(42.9) | 56(98.2) | <0.001 |
|                         | lateral fields | posterior fields | No. of involved zones | p value |
|-------------------------|----------------|------------------|-----------------------|---------|
|                         | 109(38.9)      | 9(5.9)           | 44(62.9)              | 56(98.2) <0.001 |
|                         | 139(49.6)      | 26(17.0)         | 56(80.0)              | 57(100.0) <0.001 |
| No. of involved zones   | 1[0~4]         | 0[0~1]           | 3[2~4]                | 9[7~11] <0.001 |

**Multiple coalescent B-lines**

|                         | anterior fields | lateral fields | posterior fields | p value |
|-------------------------|-----------------|----------------|-----------------|---------|
|                         | 33(11.8)        | 0(0.0)         | 1(1.4)          | 32(56.1) <0.001 |
|                         | 32(11.4)        | 0(0.0)         | 0(0.0)          | 32(56.1) <0.001 |
|                         | 34(12.1)        | 0(0.0)         | 1(1.4)          | 33(57.9) <0.001 |
| No. of involved zones   | 0[0~0]          | 0[0~0]         | 0[0~0]          | 1[0~3]  <0.001 |

**Consolidation**

|                         | anterior fields | lateral fields | posterior fields | p value |
|-------------------------|-----------------|----------------|-----------------|---------|
|                         | 17(6.1)         | 0(0.0)         | 0(0.0)          | 17(29.8) <0.001 |
|                         | 25(8.9)         | 0(0.0)         | 1(1.4)          | 24(42.1) <0.001 |
|                         | 41(14.6)        | 0(0.0)         | 2(2.9)          | 39(68.4) <0.001 |
| No. of involved zones   | 0[0~0]          | 0[0~0]         | 0[0~0]          | 2[1~5]  <0.001 |

**Left lung involved, n (%)**

|                         | 139(49.6)      | 26(17.0)        | 56(80.0)         | 57(100.0) <0.001 |

**Right lung involved, n (%)**

|                         | 140(50.0)      | 23(15.0)        | 60(85.7)         | 57(100.0) <0.001 |

**Bilateral involved, n (%)**

|                         | 103(36.8)      | 0(0.0)          | 46(65.7)         | 57(100.0) <0.001 |

Data are n (%), or Median [ IQR]. p values comparing patients with COVID-19 in different groups and normal control participants are from χ² test, or Mann-Whitney U test. p<0.05 was considered statistically significant; LUS, lung ultrasonography; COVID-19, coronavirus disease 2019.
### Table 4. LUS Findings of COVID-19 Patients With and Without adverse events

| Variables                        | All patients | Non-event | Event | p value |
|----------------------------------|--------------|-----------|-------|---------|
|                                  | (n=280)      | (n=243)   | (n=37)|         |
| **LUS features**                 |              |           |       |         |
| Pleural line, n (%)              |              |           |       |         |
| normal pleural line              | 181(64.6)    | 180(74.1) | 1(2.7)| <0.001 |
| irregular pleural line           | 99(35.4)     | 63(25.9)  | 36(97.3)| <0.001 |
| blurred pleural line             | 31(11.1)     | 6(2.5)    | 25(67.6)| <0.001 |
| B-lines, n (%)                   |              |           |       |         |
| well-spaced B-lines<3            | 250(89.3)    | 236(97.1) | 14(37.8)| <0.001 |
| well-spaced B-lines≥3            | 176(62.9)    | 139(57.2) | 37(100.0)| <0.001 |
| multiple coalescent B-lines      | 34(12.1)     | 8(3.3)    | 26(70.3)| <0.001 |
| Consolidation, n (%)             | 46(16.4)     | 22(9.1)   | 24(64.9)| <0.001 |
| Pleural effusion, n (%)          | 5(1.8)       | 3(1.2)    | 2(5.4) | 0.131   |
| **Distribution of abnormal LUS features** | | | | |
| Irregular pleural line           |              |           |       |         |
| anterior fields                  | 55(19.6)     | 25(10.3)  | 30(81.1)| <0.001 |
| lateral fields                   | 50(17.9)     | 24(9.9)   | 26(70.3)| <0.001 |
| posterior fields                 | 76(27.1)     | 49(20.2)  | 27(73.0)| <0.001 |
| No. of involved zones            | 0[0~2]       | 0[0~1]    | 7[4~10]| <0.001 |
| Blurred pleural line             |              |           |       |         |
| anterior fields                  | 4(1.4)       | 1(0.4)    | 3(8.1) | 0.008   |
| lateral fields                   | 16(5.7)      | 3(1.2)    | 13(35.1)| <0.001 |
| posterior fields                 | 28(10.0)     | 6(2.5)    | 22(59.5)| <0.001 |
| No. of involved zones            | 0[0~0]       | 0[0~0]    | 2[0~3] | <0.001 |
| Well-spaced B-lines≥3            |              |           |       |         |
| anterior fields                  | 100(35.7)    | 63(25.9)  | 37(100.0)| <0.001 |
| lateral fields                   | 109(38.9)    | 74(30.5)  | 35(94.6)| <0.001 |
| posterior fields                 | 139(49.6)    | 103(42.4) | 36(97.3)| <0.001 |
| No. of involved zones            | 1[0~4]       | 1[0~2]    | 10[6~10]| <0.001 |
| Multiple coalescent B-lines      |              |           |       |         |
|                          | anterior fields | lateral fields | posterior fields | p-value |
|--------------------------|-----------------|----------------|-----------------|---------|
| **No. of involved zones**| 0[0~0]          | 0[0~0]         | 2[0~3]          | <0.001  |
| **Consolidation**        |                 |                |                 |         |
| anterior fields          | 17(6.1)         | 5(2.1)         | 12(32.4)        | <0.001  |
| lateral fields           | 25(8.9)         | 10(4.1)        | 15(40.5)        | <0.001  |
| posterior fields         | 41(14.6)        | 19(7.8)        | 22(59.5)        | <0.001  |
| No. of involved zones    | 0[0~0]          | 0[0~0]         | 2[0~5]          | <0.001  |
| **Left lung involved, n (%)** | 139(49.6)    | 103(42.4)      | 36(97.3)        | <0.001  |
| **Right lung involved, n (%)** | 140(50.0)    | 103(42.4)      | 37(100.0)       | <0.001  |
| **Bilateral involved, n (%)** | 103(36.8)   | 67(27.6)       | 36(97.3)        | <0.001  |
| **LUS score**            | 1[0~6]          | 1[0~3]         | 32[21~49]       | <0.001  |

Data are n (%) or median[ IQR]. p values comparing patients with COVID-19 in different groups and normal control participants are from χ² test, or Mann-Whitney U test. p<0.05 was considered statistically significant; LUS, lung ultrasonography; COVID-19, coronavirus disease 2019.
Table 5. Predictors of Adverse Event in patients with COVID-19 by Cox Proportional Hazard

| Variables          | Univariate cox regression | Model 1 | Model 2 | Model 3 |
|--------------------|----------------------------|---------|---------|---------|
|                    | HR(95% CI)                 | P value | HR(95% CI) | P value | HR(95% CI) | P value |
| Age, years         | 1.081(1.057, 1.106)        | <0.001  | 1.040(1.011, 1.070) | 0.007   | 1.032(1.001, 1.063) | 0.041   | 1.028(0.999, 1.059) | 0.06   |
| Male (yes vs no)   | 1.074(0.558, 2.068)        | 0.83    | 0.994(0.453, 2.182) | 0.987   | 0.937(0.892, 0.985) | 0.01   | 0.940(0.897, 0.985) | 0.01   |
| BMI, Kg/m²         | 0.828(0.622, 1.103)        | 0.197   | 1.063(1.023, 1.076) | <0.001  | 1.049(1.001, 1.008) | 0.022   | 1.076(2.753, 42.049) | 0.001  |
| Lymphocytes%       | 0.872(0.836, 0.909)        | <0.001  | 0.892(0.853, 0.932) | <0.001  | 0.937(0.892, 0.985) | 0.01   | 0.940(0.897, 0.985) | 0.01   |
| CRP, mg/L          | 1.007(1.002, 1.012)        | 0.01    | 0.999(0.453, 2.182) | 0.987   | 0.937(0.892, 0.985) | 0.01   | 0.940(0.897, 0.985) | 0.01   |
| hs-TnI, ng/L       | 1.000(1.000, 1.001)        | 0.004   | 1.063(1.023, 1.076) | <0.001  | 1.049(1.001, 1.008) | 0.022   | 1.076(2.753, 42.049) | 0.001  |
| CK-MB, U/L         | 1.004(1.001, 1.008)        | 0.022   | 0.999(0.453, 2.182) | 0.987   | 0.937(0.892, 0.985) | 0.01   | 0.940(0.897, 0.985) | 0.01   |
| Comorbidity (yes vs no) | 4.928(2.417, 10.050) | <0.001  | 0.994(0.453, 2.182) | 0.987   | 0.937(0.892, 0.985) | 0.01   | 0.940(0.897, 0.985) | 0.01   |
| LUS score          | 1.083(1.065, 1.100)        | <0.001  | 1.049(1.023, 1.076) | <0.001  | 1.049(1.023, 1.076) | <0.001  | 1.049(1.023, 1.076) | <0.001  |
| LUS score > 12     | 4.935(15.296, 49.935)      | <0.001  | 0.994(0.453, 2.182) | 0.987   | 0.937(0.892, 0.985) | 0.01   | 0.940(0.897, 0.985) | 0.01   |
| Comorbidity (yes vs no) | 0.695(0.316, 1.528) | 10.760(2.753, 42.049) | 0.366  | 42.049 |
| AIC                | 286                        | 272     | 272     | 272     |
| C-index            | 0.866                      | 0.903   | 0.902   | 0.902   |

P < 0.05 was considered statistically significant. AIC, Akaike Information Criterion; C-index, Concordance index; CK-MB, creatine kinase muscle-brain; CRP, C-reactive protein; hs-TnI, Hypersensitive troponin I; CI, confidence interval; HR, hazard.
Figures

Figure 1

Typical lung ultrasound and corresponding lung CT images of patients with various LUS score. A: Lung images of a patient with a low LUS score; A1: normal pleural line and no B-line, score 0; A3: normal
pleural line and well-spaced B-lines $\geq 3$, score 1; A2: lung CT in the corresponding areas. B: Lung images of a patient with a moderate LUS score; B1: normal pleural line and multiple coalescent B-lines, score 2; B3: irregular pleural line and well-spaced B-lines $\geq 3$, score 2; B2: lung CT in the corresponding areas. C: Lung images of a patient with a high LUS score; C1: irregular pleural line and lung consolidation, score 4; C3: blurred pleural line and multiple coalescent B-lines, score 4; C4: blurred pleural line and lung consolidation, score 5; C6: irregular pleural line and lung consolidation, score 4; C2, C5: lung CT in the corresponding areas. (Note: Lung images of all 12 regions of each patient are not shown in the figure. The total LUS score should be calculated with a total score of 12 regions.)

![ROC curve analysis for the prediction of adverse events during hospitalization.](image)

| Variable  | AUC(95%CI)  | P-value | Cut-off | sensitivity | specificity |
|-----------|-------------|---------|---------|-------------|-------------|
| LUS score | 0.95(0.92, 0.98) | $<0.001$ | $>12$ | 91.9% | 90.5% |
| Age, years | 0.85(0.80, 0.89) | $<0.001$ | $>59$ | 86.5% | 72.8% |
| LYM%      | 0.83(0.76, 0.88) | $<0.001$ | $\leq 18.55\%$ | 75.0% | 85.9% |

**Figure 2**

ROC curve analysis for the prediction of adverse events during hospitalization. LYM%, lymphocyte percentage; ROC, receiver operating characteristic.
Figure 3

Kaplan-Meier freedom from event curves according to (A) age, (B) lymphocyte percentage (LYM%), (C) comorbidity, and (D) LUS score for the total population.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalMaterialFigure1.tif
• SupplementalMaterialFigure2.tif